Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seladelpar phase 2 study in adults with primary sclerosing cholangitis
2019-001760-30Phase 2Terminated
- Sponsor
- CymaBay Therapeutics
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Seladelpar with Placebo (2 arms). Primary endpoint: Relative change in alkaline phosphatase from baseline to Week 24. Started Jun 2019; status: terminated.
02
Drugs
seladelpar
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2019-001760-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001760-30.